Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
High sensitivity stress sensor based on hybrid materials
Vehicle display system or projection display for a motor vehicle, and calibration method
Method for preventing wheat from mycotoxin contamination
Controlling access to resources on a network
Method, apparatus or computer program for changing from scheduled to unscheduled communication modes
Process for preventing polymerization of cracked volatile products during pyrolysis and gasification
Pyrazole kinase modulators and methods of use
  Randomly Featured Patents
Spacecraft and an attitude control method for a spacecraft
Thermal airflow sensor
Evaluation facilitating circuit device
Relation to manufacture of masks and electronic parts
Beverage holder
Radio communications system, base station apparatus and method of transmission power control
Fluid drive mechanism
Portable water purifier
Method and arrangement for actuating electromechanical transducers
Socket receiving device